TUMOUR LYSIS SYNDROMES
\tjˈuːmə lˈa͡ɪsiz sˈɪndɹə͡ʊmz], \tjˈuːmə lˈaɪsiz sˈɪndɹəʊmz], \t_j_ˈuː_m_ə l_ˈaɪ_s_i_z s_ˈɪ_n_d_ɹ_əʊ_m_z]\
Sort: Oldest first
-
A syndrome resulting from cytotoxic therapy, occurring generally in aggressive, rapidly proliferating lymphoproliferative disorders. It is characterized by combinations of hyperuricemia, lactic acidosis, hyperkalemia, hyperphosphatemia and hypocalcemia.
By DataStellar Co., Ltd
Word of the day
Proto Oncogene Proteins c erbB 2
- cell surface protein-tyrosine kinase that is found to be overexpressed in significant number adenocarcinomas. It has extensive homology can heterodimerize EGF EPIDERMAL GROWTH FACTOR), 3 receptor (RECEPTOR, 3) and the 4 receptor. Activation of erbB-2 receptor occurs during heterodimer formation with a ligand-bound erbB family members. EC 2.7.11.-.